Tag Archives: ampligen
Ampligen – AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection
Clinical Trial Arena: AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection, 7 January 2021 AIM ImmunoTech has dosed its first Covid-19 ‘long hauler’ patient in the active AMP-511 Expanded Access Program (EAP) with the Ampligen (rintatolimod) … Continue reading
Effect of disease duration in a randomized phase III trial of rintatolimod, an immune modulator for ME/CFS
Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, by David R Strayer, Diane Young, William M Mitchell in PLoS ONE 15(10): e0240403, Oct 29 2020 [doi.org/10.1371/journal.pone.0240403] Research … Continue reading
Ampligen – the first drug approved in the world for ME/CFS
Health rising blog post, by Cort Johnson, 25 August, 2016: Ampligen Takes Big Step Forward – Becomes First Drug Approved Anywhere For Chronic Fatigue Syndrome Ampligen became the first drug approved for chronic fatigue syndrome (ME/CFS) anywhere in the world … Continue reading
